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OBJECTIVES This study was designed to determine the relationship between clopidogrel and early
ST-segment resolution (STRes) and the interaction of the two with clinical outcomes after
fibrinolysis.
BACKGROUND ST-segment resolution is an early noninvasive marker of coronary reperfusion.
METHODS The CLARITY–TIMI 28 (Clopidogrel as Adjunctive Reperfusion Therapy–Thrombolysis
in Myocardial Infarction 28) trial randomized 3,491 patients with ST-segment elevation
myocardial infarction (STEMI) undergoing fibrinolysis to clopidogrel versus placebo. ST-
segment resolution was defined as complete (70%), partial (30% to 70%), or none (30%).
RESULTS Electrocardiograms were valid for interpretation in 2,431 patients at 90 min and 2,087 at 180 min.
There was no difference in the rate of complete STRes between the clopidogrel and placebo
groups at 90 min (38.4% vs. 36.6% at 90 min). When patients were stratified by STRes category,
treatment with clopidogrel resulted in greater benefit among those with evidence of early STRes,
with greater odds of an open artery at late angiography in patients with partial (odds ratio [OR]
1.4, p  0.04) or complete (OR 2.0, p  0.001) STRes, but no improvement in those with no
STRes at 90 min (OR 0.89, p 0.48) (p for interaction 0.003). Clopidogrel was also associated
with a significant reduction in the odds of an in-hospital death or myocardial infarction in patients
who achieved partial (OR 0.30, p 0.003) or complete STRes at 90 min (OR 0.49, p 0.056),
whereas clinical benefit was not apparent in patients who had no STRes (OR 0.98, p  0.95)
(p for interaction 0.027). By 30 days, the clinical benefit of clopidogrel was predominately seen
in patients with complete STRes.
CONCLUSIONS Clopidogrel appears to improve late coronary patency and clinical outcomes by preventing
reocclusion of open arteries rather than by facilitating early reperfusion. (J Am Coll Cardiol
ublished by Elsevier Inc. doi:10.1016/j.jacc.2006.02.0522006;48:37–42) © 2006 by the American College of Cardiology Foundation
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ahe principal goals in the treatment of patients presenting with
T-segment elevation myocardial infarction (STEMI) with fi-
rinolytic agents are to achieve early reperfusion and to sustain
rterial patency in the days following presentation (1). The
esolution of ST-segment elevation on serial electrocardiogram
ECG) has been shown to be a simple surrogate of epicardial and
yocardial reperfusion (2–6) and improved ST-segment resolu-
ion (STRes) is a marker of good short- and long-term prognosis
3,7–10). Maintaining sustained patency after fibrinolysis is clin-
cally important because patients remain at risk for recurrent
schemia, myocardial infarction (MI), or death, likely due to
brupt reocclusion of the infarct related artery (11,12).
From the TIMI Study Group, Cardiovascular Division, *Brigham and Women’s
ospital and the †Beth Israel Deaconess Medical Center, Boston, Massachusetts; and
he ‡Department of Medicine, Harvard Medical School, Boston, Massachusetts. This
tudy was sponsored by Bristol-Myers Squibb and Sanofi-Aventis. In addition, the
IMI Study Group has received research funding from Lilly and AstraZeneca,
anufacturers of oral antiplatelet agents.d
Manuscript received January 6, 2006; revised manuscript received February 9, 2006,
ccepted February 14, 2006.In the CLARITY–TIMI 28 (Clopidogrel as Adjunctive
eperfusion Therapy–Thrombolysis In Myocardial
nfarction-28) trial, clopidogrel in combination with fi-
rinolytic treatment was shown to reduce the rate of
ccluded infarct-related artery, death, or MI, with no
ssociated increase in the rate of TIMI major and minor
leeding (13). There are several potential mechanisms by
hich clopidogrel may have improved both coronary artery
ow on late angiography and clinical outcomes. One pos-
ibility is that, like the glycoprotein IIb/IIIa inhibitors (14),
lopidogrel facilitated initial fibrinolysis and thereby im-
roved early reperfusion. Conversely, clopidogrel may have
ot improved initial fibrinolysis but instead maintained
atency over the days following fibrinolysis in arteries that
ere completely or partially opened. The CLARITY–TIMI
8 trial offers the ability to understand better the beneficial
echanism of action of clopidogrel by using early STRes as
marker of early reperfusion and using late angiography to
etermine the rate of late infarct-related artery patency (Fig. 1).
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atient selection and procedures. The CLARITY–TIMI
8 trial enrolled 3,491 patients who presented with ischemic
iscomfort at rest within 12 h before randomization, had
T-segment elevation of at least 0.1 mV in at least two
ontiguous limb leads, ST-segment elevation of at least 0.2
V in at least two contiguous precordial leads, or left
undle-branch block that was not known to be old. Inclu-
ion and exclusion criteria have been described previously
13,15). Patients were randomly assigned in a 1:1 ratio to
eceive either clopidogrel (300 mg loading dose followed by
5 mg once daily) or placebo for up to and including the day
f coronary angiography. All patients were to be treated
ith a fibrinolytic agent (selected by the treating physician);
spirin; and, for those receiving a fibrin-specific lytic agent,
eparin for 48 h. As part of a prespecified substudy, ECGs
ere performed at baseline before fibrinolysis at 90 min and
80 min after the administration of the loading dose of
tudy drug.
utcomes. Each ECG was analyzed by two investigators
t TIMI ECG Core Laboratory, who were blinded to study
reatment and outcomes, using a hand-held electronic
aliper (Fowler Inc., Newton, Massachusetts). The ST-
egment deviation was measured 20 ms after the J point in
ll leads. For anterior MI, the sum of ST-segment elevation
n leads V1 to V6, I, and aVL was added to the sum of
T-segment depression in leads II, III, and aVF. For
nferior MI, the sum of ST-segment elevation in leads II,
II, aVF (and I, aVL, V5, and V6, if present) was added to
he sum of ST-segment depression in leads V1 to V4.
Abbreviations and Acronyms
CI  confidence interval
ECG  electrocardiogram
MI  myocardial infarction
OR  odds ratio
STEMI  ST-segment elevation myocardial infarction
STRes  ST-segment resolutionigure 1. Schema of the CLARITY–TIMI 28 trial. Determination of early repe
y angiography (median 3.5 days after randomization). ECG  electrocardiogreciprocal ST-segment depression was used only in leads
ith 0.1 mV of ST-segment depression at baseline (7).
he percent resolution of ST-segment deviation from
aseline to 90 was calculated and categorized according to a
reviously described three-component definition: complete
70%) STRes, partial (30% to 70%) STRes, and no
30%) STRes (7). All coronary angiograms were analyzed
n the TIMI Angiographic Core Laboratory by readers
linded to treatment assignment, STRes, and clinical end
oints. Flow in the infarct-related artery was reported using
he TIMI flow grading system, where an occluded infarct
elated artery is defined as TIMI flow grade 0 or 1 (16). The
efinitions of recurrent MI and other efficacy end points
ave been described previously (15). Coronary angiography
as performed during the index hospitalization 48 to 192 h
median 84 h) after the start of study medication to assess
or late patency of the infarct-related artery. Patients were
ollowed clinically for 30 days.
tatistical analysis. For the comparison of baseline char-
cteristics between treatment groups, a chi-square test was
erformed for categorical variables and a Wilcoxon rank-
um test for continuous variables. All comparisons between
reatment groups were performed with a prospectively
efined logistic regression model that included terms for the
reatment group, the type of fibrinolytic agent used, the type
f heparin used, and the location of the infarct (13). The
nteractions among treatment strategy, STRes category, and
utcomes were analyzed using the previous described mul-
ivariable model with addition of an interaction term of
reatment strategy  STRes variables. The statistical sig-
ificance for interaction was derived from the difference in
he likelihood ratios between the logistic regression models
ith and without the interaction terms.
ESULTS
f the 3,491 patients enrolled in the CLARITY–TIMI 28
rial, 2,431 (70%) had ECGs both at baseline and 90 min
hat were valid for interpretation and were included in this
nalysis. Patients were excluded if their ECG had insuffi-rfusion was assessed by analyzing ST-segment resolution and late patency
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July 4, 2006:37–42 Clopidogrel, Fibrinolysis, and ST-Segment Resolutionient ST-segment deviation, revealed a left bundle-branch
lock or accelerated idioventricular rhythm, or were deter-
ined to be unreadable due to poor quality. There were no
mportant differences in baseline characteristics and initial
herapy between the two treatment groups among the 2,431
atients in whom 90-min STRes could be calculated (Table 1),
or between those with and without evaluable serial ECGs
data not shown).
ffect of clopidogrel on STRes. There was no difference
t 90 min in the degree of mean STRes between the
lopidogrel and the placebo groups (40.4% vs. 39.5% reso-
ution, p  NS), which corresponded to similar rates of
omplete STRes (38.4% vs. 36.6%, respectively [adjusted
dds ratio [OR] 1.08, 95% confidence interval [CI] 0.91 to
.29]), partial STRes (31.9% vs. 35.7%), or no STRes
29.9% vs. 28.9%). There was greater STRes among all
atients at 180 min but, again, no difference in terms of
ean STRes (55.0% vs. 57.1% resolution, p  NS) or rates
f complete STRes (52.4% vs. 53.6%, p  NS).
reatment effect of clopidogrel according to STRes
ategory. To examine the relationship between treatment
ith clopidogrel and outcomes according to the presence of
arly reperfusion, patients were stratified according to
TRes category at 90 min. Clopidogrel resulted in improved
picardial flow (TIMI flow grade 2 or 3) at late angiography
Table 1. Baseline Characteristics and Initial T
Electrocardiograms Valid for ST-Segment Res
Characteristics
Age (mean)
Age 65 yrs old
Male
Caucasian
Hypertension
Diabetes
Prior aspirin
Prior lipid-lowering agent
Presentation
SBP (mean)
HR (mean)
Anterior infarct location
High TIMI risk score (5)
Initial treatment
Time for symptom onset to lytic, h (median)
Time from lytic to study drug, min (median)
Time from baseline ECG to lytic, min (median)
Before-hospital randomization
Fibrin specific lytic
Initial heparin
Unfractionated heparin
Low-molecular-weight heparin
No heparin
Subsequent Treatment
PCI during index hospitalization
Open-label clopidogrel after discharge
Open-label ticlodipine after discharge
The p values for all comparisons are nonsignificant.
ECG  electrocardiogram; HR  heart rate; PCI  pe
TIMI  Thrombolysis In Myocardial Infarction.n all STRes categories (95.2% vs. 88.7%, adjusted OR 2.6, t5% CI 1.5 to 4.3, p  0.001 for complete STRes; 87.7%
s. 83.4%, adjusted OR 1.4, 95% CI 0.94 to 2.1, p  0.09
or partial STRes; and 80.2% vs. 73.0%, adjusted OR 1.5,
5% CI 1.0 to 2.2, p 0.03 for no STRes, p for interaction
.89) Importantly, clopidogrel resulted in greater odds of
ptimal epicardial flow (TIMI flow grade 3) in patients with
omplete or partial STRes, but no improvement in those with
o STRes (p for interaction  0.003) (Fig. 2).
In terms of clinical events, clopidogrel significantly
educed the odds of in-hospital death or MI in patients
ho achieved partial STRes (adjusted OR 0.30, 95% CI
.13 to 0.67, p  0.003) and was associated with a strong
rend in reduced risk in patients with complete STRes
adjusted OR 0.49, 95% CI 0.24 to 1.02, p  0.056),
hereas the clinical benefit of clopidogrel over placebo
as not apparent in patients who had no STRes (adjusted
R 0.98, 95% CI 0.58 to 1.68, p  0.95, interaction p 
.027) (Fig. 3).
By 30 days, treatment with clopidogrel resulted in a
ignificantly lower odds of death or MI in patients with
omplete STRes (Fig. 4A). A similar relationship was seen
or both MI and mortality alone. Patients with complete
TRes had more than 60% reduction in the odds of a
ecurrent MI (adjusted OR 0.37, 95% CI 0.20 to 0.71, p 
.002), whereas a more modest benefit was observed in
ent in Patients With Baseline and 90-min
n Analysis
Clopidogrel
(n  1,239) %
Placebo
(n  1,192) %
57.6 57.3
27.3 24.8
81.0 81.0
89.4 88.9
44.7 44.1
15.6 17.2
15.0 16.8
13.8 14.4
134.4 135.3
75.1 75.6
41.8 41.0
14.1 13.0
2.72 2.72
10 10
33 33
4.9 5.2
66.9 65.4
43.9 45.4
30.9 28.4
20.9 22.1
53.8 52.5
51.8 51.3
3.2 3.3
eous coronary intervention; SBP  systolic blood pressure;reatm
olutiohose with partial STRes (adjusted OR 0.67, 95% CI 0.32
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TRes (adjusted OR 0.80, 95% CI 0.44 to 1.45, p  0.46)
interaction p  0.93). The 30-day mortality rate was low
mong patients with complete STRes who received clopi-
ogrel (0.6%), though the benefit of clopidogrel in patients
ith complete STRes was borderline (p  0.058) and
nteraction was not significant (Fig. 4B). Similar results
ere seen with the 180-min ECGs.
ISCUSSION
n this study, we demonstrate the significant interaction
etween early STRes and the benefit of clopidogrel on
ate angiographic and clinical outcomes. Specifically,
lopidogrel did not appear to facilitate early reperfusion
s determined by STRes, but late optimal arterial flow
igure 2. Rates of Thrombolysis In Myocardial Infarction (TIMI) flow gr
 0.003 for interaction between STRes category and treatment. CI igure 3. The rates of in-hospital cardiovascular death or myocardial infarction
reatment strategy. p  0.027 for interaction between STRes category and treaTIMI flow grade 3) was improved with significantly
reater efficacy in patients with complete STRes. Anal-
gously, and consequently, clopidogrel significantly re-
uced death or recurrent MI in patients who achieved
arly STRes. Thus, our data suggest clopidogrel improves
linical outcomes by preventing reocclusion rather than
y facilitating early reperfusion.
The pharmacokinetics of clopidogrel may explain how
his drug led to significant clinical benefit by preventing
eocclusion of open arteries without facilitating early reper-
usion as detected by STRes. In platelet aggregation studies,
loading dose of 300 mg of clopidogrel begins to exert its
ull antiplatelet effects after a few hours, but this effect is not
aximal by 90 or 180 min when the serial ECGs were
ecorded. Thus, the lack of benefit on early reperfusion was
ccording to both ST-segment resolution (STRes) and treatment strategy.
ence interval; OR  odds ratio.(MI) according to both ST-segment resolution (STRes) at 90 min and
tment. CI  confidence interval; OR  odds ratio.
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July 4, 2006:37–42 Clopidogrel, Fibrinolysis, and ST-Segment Resolutionikely due to the modest additional platelet inhibition at the
ime of peak fibrinolytic activity. In prior studies of intra-
enous glycoprotein IIb/IIIa inhibitors, greater platelet
eceptor occupancy and inhibition was associated with
mproved STRes and angiographic findings (17) and re-
uced reinfarction (18), so it is not surprising that the
elatively lower platelet inhibition seen within the first hours
fter 300 mg of clopidogrel did not result in improved
eperfusion. Clopidogrel significantly improved late infarct-
elated arterial patency at a median of 3.5 days—when
lopidogrel’s full effect on inhibition of platelet inhibition
as been reached—with greater benefit in those with early
TRes. This speaks to both the dynamic nature of throm-
otic occlusions in the hours following fibrinolysis and the
enefit of sustained antiplatelet effect after reperfusion.
igure 4. The rates of cardiovascular death or myocardial infarction (MI) (
esolution (STRes) and treatment strategy. p  0.026 for interaction betw
I  confidence interval; OR  odds ratio.onger follow-up may be required to detect the clinical tenefit of an open artery in those patients with poor early
TRes (19).
The relationship between STRes and mortality is even
ore striking in regards to clopidogrel versus placebo.
atients who achieved complete STRes by 90 min and
eceived clopidogrel had a 30-day mortality rate of only
.6%, compared with 2.3% in patients receiving a placebo;
hus, patients presenting with STEMI who achieve early
omplete STRes and receive clopidogrel can be identified
ithin the first hours of hospitalization and appear to
epresent a very low-risk population. Conversely, patients
ith failed STRes may require immediate angiography.
It should be noted that the clinical benefit of clopidogrel
as apparent within the first few days of hospitalization in
he overall CLARITY–TIMI 28 trial with an early separa-
d cardiovascular death alone (B) at 30 days according to both ST-segment
TRes category and treatment for death or MI and 0.179 for death alone.A) an
een Sion of the event curves (13). Moreover, pretreatment with
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Clopidogrel, Fibrinolysis, and ST-Segment Resolution July 4, 2006:37–42lopidogrel in patients undergoing PCI, including within
h of randomization, resulted in a significant clinical
enefit (20). Finally, a statistically significant clinical benefit
f clopidogrel was also observed within the first day in the
OMMIT (Clopidogrel and Metoprolol in Myocardial
nfarction) trial, in which 45,852 patients with STEMI
ere randomized to 75 mg of clopidogrel or placebo (21).
herefore, early use of 300 mg of clopidogrel should be
iven at the time of presentation in patients without
ontraindications in order to prevent reocclusion and thus
eath and ischemic complications.
tudy limitations. Although the percentages of interpret-
ble ECGs were similar in the two treatment arms, STRes
valuations were available in 70% of the CLARITY trial
opulation. This rate of interpretable ECGs, however, is
imilar to other large STRes studies (8,18).
linical implications. The addition of clopidogrel to fi-
rinolytic agents improves angiographic and clinical out-
omes predominantly in those patients who achieve early
TRes by maintaining arterial patency and preventing
eocclusion. Because there was no increased risk of bleeding,
lopidogrel treatment with a 300-mg loading dose should be
onsidered in all patients younger than 75 years receiving
brinolysis for STEMI (and 75 mg in all patients with
TEMI based on the COMMIT trial [21]). Careful sur-
eillance of STRes in the first hours after receiving clopi-
ogrel and a fibrinolytic agent will identify patients with
ailed fibrinolysis who require immediate mechanical revas-
ularization to establish myocardial perfusion. On the other
and, patients treated with clopidogrel who achieve early
TRes are at very low risk for death or recurrent MI and do
ot appear to require an early invasive approach.
eprint requests and correspondence: Dr. Benjamin M. Scirica,
he TIMI Study Group, Cardiovascular Division, Brigham and
omen’s Hospital, 350 Longwood Avenue, 1st Floor, Boston,
assachusetts 02115. E-mail: bscirica@partners.org.
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